MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%


Healthcare US BIOL


Last update at 2024-07-11T14:24:00Z

Day Range


52 Week Range



  • Previous Close 0.09
  • Market Cap5.61M
  • Volume82252
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.66300M
  • Revenue TTM48.83M
  • Revenue Per Share TTM8.63
  • Gross Profit TTM 16.53M
  • Diluted EPS TTM-12.15


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -28.52500M -16.09300M -16.70100M -17.89900M -21.45300M
Minority interest - - - - -
Net income -28.63400M -16.15800M -16.82900M -17.85500M -21.51600M
Selling general administrative 12.31M 11.26M 9.77M 10.75M 11.77M
Selling and marketing expenses 21.68M 15.34M 11.24M 14.40M 18.12M
Gross profit 15.91M 16.53M 6.17M 14.29M 16.89M
Reconciled depreciation 0.50M 0.40M 0.50M 0.98M 0.94M
Ebit -25.33800M -16.11600M -18.53600M -15.62100M -18.20000M
Ebitda -24.84100M -15.71600M -13.82200M -14.63900M -17.25500M
Depreciation and amortization 0.50M 0.40M 4.71M 0.98M 0.94M
Non operating income net other - - 4.19M -0.12100M -0.05800M
Operating income -25.33800M -16.11600M -18.53600M -15.62100M -20.88500M
Other operating expenses 73.80M 55.30M 41.32M 53.42M 64.36M
Interest expense 2.75M 2.22M 2.36M 2.16M 0.51M
Tax provision 0.11M 0.07M 0.13M -0.04400M 0.06M
Interest income - - - 2.28M 0.57M
Net interest income -2.74900M -2.22400M -2.35900M -2.15700M -0.51000M
Extraordinary items - - - - 0.60M
Non recurring - - - - 1.50M
Other items - - - - -
Income tax expense 0.11M 0.07M 0.13M -0.04400M 0.06M
Total revenue 48.46M 39.19M 22.78M 37.80M 46.16M
Total operating expenses 41.25M 32.65M 24.71M 29.91M 35.09M
Cost of revenue 32.55M 22.66M 16.61M 23.51M 29.26M
Total other income expense net -3.18700M 0.02M 1.83M -2.27800M -2.74300M
Discontinued operations - - - - -
Net income from continuing ops -28.63400M -16.15800M -16.82900M -17.85500M -21.51600M
Net income applicable to common shares - -16.70400M -34.20700M -17.85500M -21.51600M
Preferred stock and other adjustments - - 17.38M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 35.10M 38.19M 55.28M 41.02M 31.85M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.38M 3.05M 2.01M 3.02M 1.16M
Total liab 35.35M 33.30M 30.08M 31.00M 31.47M
Total stockholder equity -0.24700M 4.89M 25.21M 10.03M 0.38M
Deferred long term liab - - - 0.37M 0.44M
Other current liab 7.99M 9.21M 7.87M 6.36M 4.74M
Common stock 0.00300M 0.00800M 0.15M 0.10M 0.03M
Capital stock 2.21M 0.00800M 0.19M 0.22M 0.03M
Retained earnings -316.80000M -296.16800M -267.53400M -251.37600M -234.54700M
Other liab - 1.14M 1.18M 1.81M 1.72M
Good will 2.93M 2.93M 2.93M 2.93M 2.93M
Other assets - 0.26M 0.22M 2.21M 0.43M
Cash 6.57M 4.18M 29.97M 17.56M 5.79M
Cash and equivalents - - - - -
Total current liabilities 19.66M 17.81M 13.84M 11.22M 25.78M
Current deferred revenue 2.45M 2.11M 2.26M 1.91M 2.24M
Net debt 11.34M 10.87M -14.92000M 0.40M 7.68M
Short term debt 3.15M 0.70M 0.41M 0.30M 13.47M
Short long term debt 2.27M 0.70M - - 13.47M
Short long term debt total 17.91M 15.05M 15.05M 17.96M 13.47M
Other stockholder equity 314.90M 301.78M 293.18M 261.57M 231.63M
Property plant equipment - 6.05M 2.78M 2.76M 1.19M
Total current assets 24.86M 28.96M 49.35M 35.11M 27.02M
Long term investments - - - - -
Net tangible assets - - 22.25M 6.98M 1.42M
Short term investments - - - - -
Net receivables 5.48M 5.84M 4.24M 3.06M 8.76M
Long term debt 11.78M 13.09M 13.60M 16.19M -
Inventory 11.43M 15.88M 12.93M 11.16M 10.99M
Accounts payable 6.07M 5.79M 3.31M 2.65M 5.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.55300M -0.73300M -0.62300M -0.38500M -0.70100M
Additional paid in capital - - - - -
Common stock total equity - - - 0.10M 0.03M
Preferred stock total equity - - - 0.12M -
Retained earnings total equity - - - -251.37600M -234.54700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.27M 0.26M 0.22M 0.23M 0.43M
Deferred long term asset charges - - - - -
Non current assets total 10.24M 9.23M 5.93M 5.92M 4.83M
Capital lease obligations 1.66M 1.90M 1.85M 1.77M 0.32M
Long term debt total - - - 16.19M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -3.72700M -0.70700M -0.09600M -0.20700M -0.52200M
Change to liabilities -0.05900M 2.07M -2.48600M -3.15600M 1.76M
Total cashflows from investing activities - -0.70700M -0.09600M -0.20700M -0.52200M
Net borrowings -1.00000M -1.00000M 2.44M 2.37M 11.40M
Total cash from financing activities 4.60M 29.95M 24.35M 10.72M 11.23M
Change to operating activities -1.13500M 0.28M 0.82M 0.44M -0.02500M
Net income -28.63400M -16.15800M -16.82900M -17.85500M -21.51600M
Change in cash -25.99400M 12.30M 11.78M -2.25500M -3.54000M
Begin period cash flow 30.18M 17.88M 6.10M 8.36M 11.90M
End period cash flow 4.18M 30.18M 17.88M 6.10M 8.36M
Total cash from operating activities -26.76100M -16.71000M -12.79500M -12.74600M -14.14700M
Issuance of capital stock 5.60M 14.42M 9.61M 9.17M 0.00000M
Depreciation 0.50M 0.40M 0.50M 0.98M 0.94M
Other cashflows from investing activities - - - - 0.04M
Dividends paid -0.21700M -0.54600M -17.37800M - -
Change to inventory -5.75400M -1.37500M -0.87100M 0.84M -0.12700M
Change to account receivables -1.64300M -0.97800M 4.29M 0.66M -1.45800M
Sale purchase of stock - - 17.38M 9.18M -0.16100M
Other cashflows from financing activities 0.22M 16.08M 21.14M 1.55M 14.98M
Change to netincome 5.25M -1.47200M -0.35600M 4.86M 6.10M
Capital expenditures 3.73M 0.71M 0.10M 0.21M 0.56M
Change receivables - - 4.29M 0.66M -1.45800M
Cash flows other operating - - 1.83M 0.60M -0.18500M
Exchange rate changes - - 0.32M -0.02300M -0.10600M
Cash and cash equivalents changes - - 11.78M -2.25500M -3.54000M
Change in working capital -5.07000M 0.00500M 1.75M -1.10800M -0.00900M
Stock based compensation 2.30M 1.66M 3.37M 2.74M 2.77M
Other non cash items 4.14M 0.99M 0.50M 2.49M 3.69M
Free cash flow -30.48800M -17.41700M -12.89100M -12.95300M -14.70500M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
-0.0059 6.94% 0.08 - - 0.10 0.77 0.33 -1.04
Abbott Laboratories
0.47 0.46% 103.53 37.15 23.15 4.67 4.97 4.88 19.38
Stryker Corporation
0.96 0.28% 338.30 44.07 24.94 5.51 6.12 6.05 25.73
Medtronic PLC
0.92 1.19% 77.98 26.60 15.87 3.35 2.08 3.90 14.12
Boston Scientific Corp
0.09 0.11% 77.19 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News


BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.


27042 Towne Centre Drive, Foothill Ranch, CA, United States, 92610-2811

Key Executives

Name Title Year Born
Mr. John R. Beaver Pres, CEO & Director 1961
Ms. Jennifer Bright Chief Financial Officer 1971
Mr. Steven Sandor Chief Operating Officer 1980
Mr. Matthew Wilson VP of HR NA
Dr. Russell Morrow D.D.S. Chief Dental Officer NA
Mr. Michael C. Carroll Corp. Sec. 1972
Mr. David Rodriguez Director of Education & Events NA
Mr. John R. Beaver President, CEO & Director 1961
Ms. Jennifer Bright Chief Financial Officer 1972
Mr. Steven Sandor Chief Operating Officer 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.